课题基金 / 基金详情

Chronic Ethanol Consumption and Pulmonary Immune Suppression

Chronic Ethanol Consumption and Pulmonary Immune Suppression
慢性乙醇消耗与肺部免疫抑制
批准号:
8729464
负责人:
Kevin L Legge
金额:
$17.39万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-05 至 2016-04-30

项目摘要

项目成果

Kevin L Legge的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):众所周知,酗酒者患呼吸道疾病的几率增加。此外,慢性酒精中毒容易引发呼吸道感染后的严重疾病。事实上,细菌性肺炎是这种易感性增加的研究最多的例子之一,与非酒精性肺炎患者相比,酗酒者的死亡率高出2至7倍。酗酒还会增加与此类感染相关的发病率。虽然许多研究详细说明了酗酒者在呼吸道感染期间疾病严重程度的增加,但对慢性乙醇(Etoh)摄入介导疾病严重程度增加的潜在机制或酒精如何改变肺适应性免疫反应的了解要少得多。甲型流感病毒(IAV)感染是对人类健康的严重挑战,众所周知,它使个人更容易患上肺炎。有趣的是,我们先前的研究表明,长期食用乙醇会增加流感相关的发病率和死亡率。此外,我们的结果表明,这种疾病严重性的增加与呼吸道树突状细胞(RDC)以及流感特异性CD8 T细胞反应的缺陷或改变有关。鉴于目前流行性和大流行性流感的威胁以及酗酒者中链球菌感染的持续威胁,更好地了解酒精引起的肺适应性免疫反应中的损害可能导致提高这些人对这些重要人类病原体的免疫力的方法。因此,我们的长期目标是确定慢性乙醇在呼吸适应性免疫反应中诱导了哪些损害,并确定了克服这些损害的方法,以防止严重和致命的疾病。在此应用程序中,我们将继续 使用Meadow-Cook慢性乙醇模型以及我们的流感病毒(IAV)和链球菌(GAS)感染的小鼠模型来实现这一目标。我们的中心假设是CD8 T细胞内的缺陷是慢性无水乙醇小鼠呼吸道感染严重程度增加的原因。我们提出了以下具体目标:目的1.确定在长期饮用乙醇的过程中,接种IAV疫苗是否能增强CD8 T细胞免疫功能,预防与IAV感染相关的疾病;目的2.确定乙醇在GAS或IAV+GAS感染过程中如何改变肺部炎症和CD8 T细胞免疫的动力学、程度和特征。这一应用不仅将确定慢性无水乙醇在IAV和GAS感染期间在肺适应性免疫中所造成的缺陷,而且还将增加我们对慢性无水乙醇在其他呼吸道感染中存在的免疫的一般理解。此外,从这项申请中学到的见解有可能建议恢复和/或提高慢性酗酒者在这些疾病期间的免疫力的方法。
英文摘要
DESCRIPTION (provided by applicant): It is well known that alcoholics have an increased incidence of respiratory diseases. Furthermore, chronic alcoholism predisposes for severe disease following respiratory infections. Indeed, bacterial pneumonias, among the best-studied examples of this increased predisposition, result in a 2 to 7-fold greater incidence in mortality i alcoholics compared to non-alcoholic pneumonia patients. Alcohol abuse additionally increases the morbidity associated with such infections. While many studies have detailed the increase in disease severity during respiratory infections in alcoholics, much less is understood about the underlying mechanisms through which chronic ethanol (EtOH) consumption mediates this increase in disease severity or how alcohol alters pulmonary adaptive immune responses. Influenza A virus (IAV) infections represent a serious challenge to human health and are known to predispose individuals to an increased incidence of pneumonia. Interestingly, our prior studies indicate that chronic consumption of EtOH increases both influenza associated morbidity and mortality. Further, our results suggest that this increased severity of disease is related to defects or alterations in both respiratory dendritic cells (rDC) as well as influenza- specific CD8 T cell responses. Given the current threat of both epidemic and pandemic influenza as well as the ongoing threat of Streptococcal infections in alcoholics a better understanding of the alcohol induced lesions within the pulmonary adaptive immune response could lead to methodologies to boost immunity to these important human pathogens in these individuals. Therefore our long-range goal is to determine what lesions chronic EtOH induces within the respiratory adaptive immune response and determine methodologies to overcome these lesions to protect from severe and fatal disease. Within this application we will continue to use the Meadow-Cook chronic EtOH model as well as our mouse models of influenza virus (IAV) and Streptococcus (GAS) infection toward this goal. Our central hypothesis is that defects within CD8 T cells are responsible for the increased severity of respiratory infections in chronic EtOH mice. We propose the following Specific Aims: Aim 1. Determine if vaccination against IAV can enhance CD8 T cell immunity and prevent the enhanced disease associated with IAV infections during chronic EtOH consumption; Aim 2. Determine how ethanol alters the kinetics, magnitude, character of pulmonary inflammation, and CD8 T cell immunity during GAS or IAV+GAS infections. This application will not only define the defects that chronic EtOH creates in pulmonary adaptive immunity during infections with IAV and GAS but should also increase our general understanding of immunity in the presence of chronic EtOH during other respiratory infections. Furthermore, the insights learned from this application hold the potential to suggest methodologies to restore and/or boost immunity in chronic alcoholics during these diseases.
期刊论文(12)
专著(0)
科研奖励(0)
会议论文
Evaluation of hydrophobic micro-zeolite-mixed matrix membrane and integrated with acetone-butanol-ethanol fermentation for enhanced butanol production.
疏水性微沸石混合基质膜与丙酮-丁醇-乙醇发酵相结合以提高丁醇产量的评估
DOI: 10.1186/s13068-015-0288-x
发表时间: 2015
期刊: Biotechnology for biofuels
影响因子: 6.3
作者: [Xue C, Yang D, Du G, Chen L, Ren J, Bai F]
通讯作者: Bai F
A novel point mutation in RpoB improves osmotolerance and succinic acid production in Escherichia coli.
RpoB 中的一个新点突变可改善大肠杆菌的渗透压耐受性和琥珀酸产量。
DOI: 10.1186/s12896-017-0337-6
发表时间: 2017-02-13
期刊: BMC biotechnology
影响因子: 3.5
作者: [Xiao M, Zhu X, Xu H, Tang J, Liu R, Bi C, Fan F, Zhang X]
通讯作者: Zhang X
Systematic manipulation of glutathione metabolism in Escherichia coli for improved glutathione production.
系统地操纵大肠杆菌中的谷胱甘肽代谢以提高谷胱甘肽的产量。
DOI: 10.1186/s12934-016-0439-1
发表时间: 2016-02-16
期刊: Microbial cell factories
影响因子: 6.4
作者: [Zhang J, Quan C, Wang C, Wu H, Li Z, Ye Q]
通讯作者: Ye Q
DOI: 10.1186/s13068-015-0295-y
发表时间: 2015
期刊: Biotechnology for biofuels
影响因子: 6.3
作者: [Gao J, Yuan W, Li Y, Xiang R, Hou S, Zhong S, Bai F]
通讯作者: Bai F
共 10 条
    Protection and Immunity after Polyanhydride Nanoparticle Vaccination against Avian Influenza A Virus
    • 批准号:
      10584130
    • 项目类别:
    • 资助金额:
      $77.0万
    • 财政年份:
      2022
    • 负责人:
      Kevin L Legge
    • 依托单位:
    Nanovaccine-Mediated Immune Protection Against Influenza Virus
    • 批准号:
      10172830
    • 项目类别:
    • 资助金额:
      $68.09万
    • 财政年份:
      2017
    • 负责人:
      Kevin L Legge
    • 依托单位:
    Nanovaccine-Mediated Immune Protection Against Influenza Virus
    • 批准号:
      9383422
    • 项目类别:
    • 资助金额:
      $48.27万
    • 财政年份:
      2017
    • 负责人:
      Kevin L Legge
    • 依托单位:
    Chronic Alcohol Alteration of Influenza-Specific CD8 T cell Immunity and Protection
    • 批准号:
      9090516
    • 项目类别:
    • 资助金额:
      $21.77万
    • 财政年份:
      2016
    • 负责人:
      Kevin L Legge
    • 依托单位:
    海外基金